Chiasma (NASDAQ:CHMA) PT Set at $18.00 by Cantor Fitzgerald

Chiasma (NASDAQ:CHMA) received a $18.00 target price from research analysts at Cantor Fitzgerald in a report released on Friday, TipRanks reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 242.86% from the stock’s current price.

Several other research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chiasma in a research note on Tuesday, July 23rd. ValuEngine downgraded Chiasma from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Brookline Capital Management reissued a “buy” rating on shares of Chiasma in a research note on Wednesday, July 24th. Piper Jaffray Companies initiated coverage on Chiasma in a research note on Wednesday, July 31st. They set an “overweight” rating and a $11.00 target price for the company. Finally, Zacks Investment Research downgraded Chiasma from a “buy” rating to a “hold” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Chiasma has a consensus rating of “Buy” and a consensus price target of $12.35.

NASDAQ CHMA traded up $0.03 during trading on Friday, hitting $5.25. 149,616 shares of the company’s stock were exchanged, compared to its average volume of 377,214. The company has a market cap of $219.85 million, a PE ratio of -4.10 and a beta of 1.19. Chiasma has a fifty-two week low of $2.11 and a fifty-two week high of $9.25. The stock’s 50 day moving average price is $5.19 and its two-hundred day moving average price is $6.08.

Chiasma (NASDAQ:CHMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. On average, equities analysts predict that Chiasma will post -1.09 earnings per share for the current year.

In other news, Director Scott Minick acquired 9,818 shares of the stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $5.19 per share, with a total value of $50,955.42. Following the completion of the purchase, the director now directly owns 62,531 shares of the company’s stock, valued at approximately $324,535.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roni Mamluk sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $6.35, for a total value of $63,500.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $63,500. The disclosure for this sale can be found here. Corporate insiders own 8.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP increased its stake in shares of Chiasma by 151.0% in the second quarter. Susquehanna International Group LLP now owns 56,649 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 34,080 shares during the period. Citadel Advisors LLC acquired a new position in shares of Chiasma in the second quarter valued at approximately $145,000. Cubist Systematic Strategies LLC increased its stake in shares of Chiasma by 35.4% in the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,722 shares during the period. Invesco Ltd. acquired a new position in shares of Chiasma in the second quarter valued at approximately $186,000. Finally, Vanguard Group Inc. increased its stake in shares of Chiasma by 30.9% in the second quarter. Vanguard Group Inc. now owns 1,051,908 shares of the biotechnology company’s stock valued at $7,858,000 after buying an additional 248,574 shares during the period. 52.97% of the stock is owned by institutional investors.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Further Reading: Do back-end load funds outperform no-load funds?

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.